+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Australia Diabetes Care Devices Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 5175827
  • Report
  • August 2020
  • Region: Australia
  • 75 Pages
  • Mordor Intelligence


  • Abbott Diabetes Care
  • AgaMatrix Inc.
  • Arkray
  • Ascensia Diabetes Care
  • Dexcom
  • Eli Lilly
The Australia Diabetes Care Devices Market is expected to reach more than USD 0.7 billion by 2025, at a CAGR greater than 9%. Monitoring devices are anticipated to dominate the market during the forecast period, owing to the rising prevalence of diabetes and an increase in the number of device users in the country. There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps. Technological innovations and advances give many conveniences in measuring blood glucose levels.

Key Market Trends

Increasing Diabetes Population at high rate

The prevalence of diabetes in Australia has more than tripled between 1989-2019. In 2019, Australia had about 1.36 million diabetic patients. In 2019, Type-1 diabetes patients accounted for 8.97% of the total diabetic population in Australia. Due to the early age and longer diabetes duration, the youth is at risk of developing diabetes at a younger age, which lessens their quality of life, shortens life expectancy, and increases healthcare costs of the society. Hence, the demand for oral anti-diabetes drugs market has been on the rise, and its adoption rate is seen increasing, which has been driving the market. Also, with the increasing awareness among Type-2 diabetes patients worldwide, the demand for the Diabetes Devices market has been rising at a rapid pace.

Sensors Occupy the Highest Share in the Australia Continuous Glucose Monitoring Devices Segment

In the Australian CGM market, sensors are having the highest share. Since, 2016 Federal Election, the government has worked to subsidize continuous glucose monitoring (CGM) technology for patients with Type-1 diabetes. The Australian government now provides access to subsidized continuous glucose monitoring (CGM) products through the National Diabetes Services Scheme (NDSS). The different CGM systems available in Australia include Dexcom G5, MiniMed 640G, Medtronic 670G, and Guardian Connect CGM. The innovations in the Sensors market are driving the growth of the segment in the forecast period. Some of the innovations are Eversense CGM System, an implantable glucose sensor by Senseonics, Incorporated was launched in 2018. The advantage of the Eversense CGM System is that it can remain in place for up to three months, where the other CGMs sensors remain in place up to 3-10 days.​

Competitive Landscape

There have been constant innovations driven by manufacturers to compete in the market. The major players, such as Abbott and Medtronic, have undergone many mergers, acquisitions, and partnerships, to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. The manufacturers of insulin delivery devices are spending a massive amount on the R&D of the devices. For example, in Feb 2020, Abbott and Insulet partnered to integrate Abbott's glucose-sensing technology with Insulet's tubeless system, the Omnipod Horizon Automated Insulin Delivery (AID) System (Omnipod Horizon System), to offer personalized automated insulin delivery and care for people living with diabetes.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown


  • Abbott Diabetes Care
  • AgaMatrix Inc.
  • Arkray
  • Ascensia Diabetes Care
  • Dexcom
  • Eli Lilly

1.1 Study Assumptions
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.3 Industry Attractiveness - Porter's Five Forces Analysis
4.3.1 Bargaining Power of Suppliers
4.3.2 Bargaining Power of Consumers
4.3.3 Threat of New Entrants
4.3.4 Threat of Substitute Products and Services
4.3.5 Intensity of Competitive Rivalry
5.1 Monitoring Devices (Value and Volume, 2012-2025)
5.1.1 Self-monitoring Blood Glucose Devices (Hospital Use and Home Use) Glucometer Devices (Hospital and Home Use) Blood Glucose Test Strips (Hospital and Home Use) Lancets (Hospital and Home Use)
5.1.2 Continuous Glucose Monitoring Devices Sensors Durables (Receivers and Transmitters)
5.2 Management Devices (Value and Volume, 2012-2025)
5.2.1 Insulin Delivery Devices Insulin Pump Device Insulin Pump Monitor Insulin Pump Reserviour Insulin Ifusion Sets Insulin Syringes Insulin Disposable Pens Insulin Cartridges in Reusable Pens Jet Injectors
6.1 Type-1 Diabetes Population (2012-2025)
6.2 Type-2 Diabetes Population (2012-2025)
7.1.1 Novo Nordisk A/S
7.1.2 Sanofi Aventis
7.1.3 Eli Lilly
7.1.4 F. Hoffmann-La Roche Ltd
7.1.5 Abbott Diabetes Care
7.1.6 Johnson and Johnson (Lifescan)
7.1.7 Arkray
7.1.8 Ascensia Diabetes Care
7.1.9 AgaMatrix Inc.
7.1.10 Dexcom
7.1.11 Medtronic
7.1.12 Ypsomed Holding AG
7.2.1 Novo Nordisk A/S
7.2.2 Sanofi Aventis
7.2.3 Eli Lilly
7.2.4 F. Hoffmann-La Roche Ltd
7.2.5 Abbott Diabetes Care
7.2.6 Johnson and Johnson (Lifescan)
7.2.7 Dexcom
7.2.8 Medtronic
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Novo Nordisk A/S
  • Sanofi Aventis
  • Eli Lilly
  • F. Hoffmann-La Roche Ltd
  • Abbott Diabetes Care
  • Johnson and Johnson (Lifescan)
  • Arkray
  • Ascensia Diabetes Care
  • AgaMatrix Inc.
  • Dexcom
  • Medtronic
  • Ypsomed Holding AG
Note: Product cover images may vary from those shown